Loerzweiler, Germany

Michael Cahill

USPTO Granted Patents = 3 


Average Co-Inventor Count = 2.5

ph-index = 1

Forward Citations = 6(Granted Patents)


Company Filing History:


Years Active: 2010-2013

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Michael Cahill: Innovator in Cancer Diagnosis and Treatment

Introduction

Michael Cahill is a notable inventor based in Loerzweiler, Germany. He has made significant contributions to the field of cancer diagnosis and treatment, holding a total of 3 patents. His work focuses on innovative methods that aim to improve the detection and treatment of various cancers.

Latest Patents

Cahill's latest patents include a method involving Annexin A3 for cancer diagnosis. This method treats urogenital and/or intestinal tract cancer by administering a therapeutically effective amount of at least one annexin protein, specifically Annexin A3, to a mammal. Another significant patent relates to the use of substances for treating tumors. This invention encompasses the use of an active ingredient and a method for the prevention or treatment of tumors, as well as the diagnostic detection of disorders associated with these tumors, along with related pharmaceutical compositions and kits.

Career Highlights

Michael Cahill is currently associated with Proteosys AG, where he continues to advance his research and innovations in cancer treatment. His work has garnered attention for its potential impact on improving patient outcomes in oncology.

Collaborations

Cahill has collaborated with notable colleagues, including André Schrattenholz and Wojciech Wozny, contributing to a dynamic research environment focused on cancer therapies.

Conclusion

Michael Cahill's innovative work in cancer diagnosis and treatment exemplifies the importance of research and development in the medical field. His patents reflect a commitment to improving healthcare solutions for cancer patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…